| Objective:To explore the Influence of different doses of rosuvastatin on serum inflammatory cytokines levels and
prognosis in acute coronary syndrome (ACS) patients.Methods:120 cases of ACS from May 2014 to October 2015 were collected and
randomly divided into A,B and C groups, each with 40 cases. Based on the treatments with oxygen inhalation,anticoagulation, and coronary
vessels expansion treatments with each group, A group was given 20 mg/d of pravastatin through oral administration, B group given
10 mg/d of rosuvastatin, and C group given 20 mg/d of rosuvastatin, which each group was treated with 6 month. Serum lipid level, hypersensitive
C-reactive protein (hs-CRP), tumor necrosis factor alpha(TNF-alpha) and interleukin-6 (IL-6) of the three groups were compared
before and after treatment, meanwhile the major cardiovascular events (MACE) and adverse reactions were observed.Results:The
hs-CRP, TNF-琢, IL-6 levels of three groups of patients after treatment were significantly lower, and group C had the greatest reduction,
followed by group B patients, which comparative differences were statistically significant (P<0.05); Three groups after treatment in patients
with blood lipid levels were improved, and improve the most obvious group C, followed by group B, which comparative differences
were statistically significant (P<0.05); Followed up for 6 months,the incidence of cardiovascular events of group C was 2.5%,
which was far lower than group B (10.0%) and group A (20.0%) with significant difference (P<0.05).Conclusion:High-dose(20mg/d)rosuvastatin
can significantly decrease inflammation in ACS patients, with effective and safety regulation of serum lipids, which could be
used in the treatment of ACS patients. |
